You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 百心安-B(2185.HK)大漲14%創上市新高 二代Iberis腎神經阻斷(RDN)系統擬於歐洲CERC臨牀試驗
格隆匯 01-03 10:47
格隆匯1月3日丨百心安-B(2185.HK)平開高走,盤中高見32港元創上市新高,現漲14.6%報31港元,最新市值75億港元。百心安-B曾於12月29日公佈,公司已與歐洲心血管研究中心(CERC)訂約進行一項歐洲臨牀試驗,評估公司的第二代Iberis腎神經阻斷(RDN)系統。公司表示,第二代Iberis是其自主開發的第二代RDN系統,為世界上唯一為醫生及患者提供經股動脈及經橈動脈介入(TRI)方法的RDN在研產品。CERC是一家合約研究組織,專注於心血管裝置的臨牀試驗。另據聯交所權益披露資料顯示,百心安-B於12月23日獲CORNWELL(HONG KONG)LIMITED在場內涉資約7665.9萬港元增持360.75萬股,增持後,其持股比例由0%上升至5.86%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account